Key Financial Figures

Profitability Metrics:

  • Operating Revenue: ₹840.8 crore, up 35.6% YoY from ₹620.0 crore in Q1FY26
  • Gross Profit: ₹497.3 crore, up 38.9% YoY with Gross Margin of 59.1% (138 bps improvement YoY)
  • EBITDA: ₹213.0 crore, up 112.8% YoY with EBITDA Margin of 25.3% (919 bps improvement YoY)
  • PAT: ₹159.4 crore, up 173.9% YoY with Net Margin of 18.4% (910 bps improvement YoY)
  • EPS: ₹3.5, up 169.5% YoY from ₹1.3

Balance Sheet & Cash Flow:

  • Cash balance: ₹1,058 crore as of June 30, 2026 (first time crossing ₹1,000 crore)
  • Net cash: ₹1,031 crore
  • Cash generated from operations: ₹185 crore in Q1FY27
  • Net Capex: ₹33 crore incurred during Q1FY27
  • Free cash flow: ₹152 crore
  • Working capital cycle: 132 days for Q1FY27 (improved from 159 days in Q1FY26)
  • R&D spends: ₹23 crore (2.8% of consolidated revenue)

Regional Business Performance

US & North America:

  • Revenue: ₹377.2 crore, up 15.1% YoY
  • Contribution: ~45% of consolidated revenue
  • Growth supported by healthy order book and new launches

UK & Europe:

  • Revenue: ₹356.0 crore, up 74.7% YoY (highest-ever quarterly revenue)
  • QliniQ B.V. (Netherlands) contributed ₹44 crore in Q1FY27
  • Growth supported by new launches and market-share gains

Australia & New Zealand:

  • Revenue: ₹88.0 crore, up 53.7% YoY
  • Growth supported by portfolio expansion and new product launches

Rest of World (ROW):

  • Revenue: ₹20.0 crore, down 36.8% YoY but up 6.0% QoQ (first sequential improvement in four quarters)
  • Middle East shipments impacted by delays; potential recovery with improving geopolitical conditions

Strategic Developments

  • Completed acquisition of 100% of QliniQ B.V. and ABCnow in Europe
  • Europe emerging as significant new growth engine with establishment of front-end presence
  • Company focusing on scaling businesses across geographies, accelerating new launches, and strengthening European platform

Credit Rating Update

  • India Ratings and Research (Fitch Group) revised outlook on company's bank loan facilities to Positive from Stable
  • Ratings affirmed at IND AA-/IND A1+

Forward Calendar

  • Earnings conference call scheduled for August 13, 2026, at 4:30 pm IST
  • Transcript will be available at www.marksanspharma.com